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ABSTRACT
Mitochondrial DNA depletion syndromes (MDS) are often serious
autosomal recessively inherited disorders characterized by tissue-
specific mtDNA copy number reduction. Many genes, including
MPV17, are associated with the hepatocerebral form of MDS.MPV17
encodes for a mitochondrial inner membrane protein with a poorly
characterized function. Several MPV17 mutations have been
reported in association with a heterogeneous group of early-onset
manifestations, including liver disease and neurological problems.
Mpv17-deficient mice present renal and hearing defects.We describe
here a MPV17 truncation mutation in dogs. We found a 1-bp insertion
in exon 4 of the MPV17 gene, resulting in a frameshift and early
truncation of the encoded protein. The mutation halves MPV17
expression in the lymphocytes of the homozygous dogs and the
truncated protein is not translated in transfected cells. The insertion
mutation is recurrent and exists in many unrelated breeds, although is
highly enriched in the Boxer breed. Unexpectedly, despite the
truncation of MPV17, we could not find any common phenotypes in
the genetically affected dogs. The lack of observable phenotype
could be due to a late onset, mild symptoms or potential tissue-
specific compensatory mechanisms. This study suggests species-
specific differences in the manifestation of the MPV17 defects and
establishes a novel large animal model to further study MPV17
function and role in mitochondrial biology.
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INTRODUCTION
Improper mitochondrial DNA (mtDNA) replication and production
of deoxyribonucleotide triphosphate (dNTP) pools are associated
with mtDNA depletion syndromes (MDSs). These depletion
syndromes are characterized by tissue-specific reduction of
mtDNA copy number, which may result in serious organ failure
(Spinazzola et al., 2006). Recessive defects in at least twelve nuclear
genes TYMP, POLG1, POLG2, PEO1 (Twinkle), SLC25A4,
DGUOK, TK2, SUCLA2, MPV17, SUCLG1, OPA1 and RRM2B
have been associated with the MDSs (Nishino et al., 1999; Mandel
et al., 2001; Saada et al., 2001; Van Goethem et al., 2001; Elpeleg
et al., 2005; Spinazzola et al., 2006; Bourdon et al., 2007; Hakonen
et al., 2007; Sarzi et al., 2007; Uusimaa et al., 2013). Clinically
MDSs are classified into three main forms: myopathic (OMIM
#609560), encephalomyopathic (OMIM #612073, #612075,
#245400), and hepatocerebral form (OMIM #251880). The latter
is associated with mutations in the PEO1 (Twinkle), POLG1,
DGUOK and MPV17 genes (Spinazzola et al., 2009).
MPV17 is a ubiquitously expressed nuclear gene (Spinazzola
et al., 2006), which belongs to the MPV17/PMP22 family of
transmembrane proteins (Trott and Morano, 2004). It encodes a
highly conserved 176-amino acid transmembrane protein in the
inner mitochondrial membrane (Spinazzola et al., 2006; Viscomi
et al., 2009). MPV17 function is not well established but it most
likely participates in mtDNA maintenance and metabolism of
reactive oxygen species (Zwacka et al., 1994; Krick et al., 2008;
Viscomi et al., 2009).
Over 30 different MPV17 mutations have been found in human
hepatocerebral form of MDS (Uusimaa et al., 2013). These
mutations cause respiratory enzyme chain deficiency leading to
dysfunction of oxidative phosphorylation system and mtDNA
depletion in a tissue-specific manner (Spinazzola et al., 2009).
Patients with different MPV17 mutations have been clinically
diagnosed mainly with infantile- or childhood-onset progressive
liver failure, neurological symptoms, hypoglycaemia and elevated
blood lactate (Karadimas et al., 2006; Spinazzola et al., 2006,
2008; Wong et al., 2007; Navarro-Sastre et al., 2008; Kaji et al.,
2009; Parini et al., 2009; El-Hattab et al., 2010; AlSaman et al.,
2012). Recent studies have associated MPV17 mutations also with
adult-onset neuropathy and leukoencephalopathy (Blakely et al.,
2012; Garone et al., 2012).Mpv17-deficient mice were reported to
manifest kidney disease without a renal failure, early-onset
deafness, coat color changes and shorter lifespan (Müller et al.,
1997; Viscomi et al., 2009; Meyer zum Gottesberge et al., 2012).
We studied MPV17 here as a candidate gene in a Chihuahua
dog with neuropathy and hepatocerebral MDS-like symptoms
but eventually ended up with an incidental finding unrelated to
the Chihuahuas. MPV17 mutation screening resulted in the
identification of a 1-bp change in the beginning of exon 4 in the
affected Chihuahua compared to the reference Boxer sequence
(CamFam2.0). However, further screening of additional Chihuahuas
and Boxers demonstrated that the change is not associated with
Chihuahuas but present as an insertion mutation in the Boxer breed
with high frequency. The fact that MPV17 defects should lead to
severe hepatocerebral formofMDSembarkedus to study the presence
of the mutation in other breeds, study its functional consequences at
RNAandprotein level, and to findpossible associationswith expected
MDS-like disease phenotypes in the genetically affected dogs.
RESULTS
MPV17 insertion mutation
A 3-year old Spanish Chihuahua was clinically diagnosed with
symptoms that partially resembled those of hepatocerebral MDS
and MPV17 was selected as a candidate gene for mutation
screening. Exonic sequencing revealed a 1-bp deletion in theReceived 4 August 2015; Accepted 12 August 2015
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beginning of exon 4 as compared with the reference Boxer sequence
(CanFam2.0, XM_848683.1). Additional 42 normal Chihuahua
from our DNA bank were then screened for the 1-bp change to
confirm the discovery. This screening revealed that also all normal
Chihuahua samples had the same sequence as the case dog. The
reference Boxer sequence (XM_848683.1) had seven consecutive
guanine bases (Gs) while the Chihuahuas had only six Gs. Seven Gs
leads to a frameshift while six Gs maintains the established open
reading frame in MPV17. This was an unexpected result and
suggested that there might be either a sequence ambiguity in the
database reference or mutation in Boxers. We genotyped additional
180 Boxers and found 46 dogs with 6 Gs (26%), 94 dogs that were
heterozygotes 6 or 7 Gs (52%) and 40 dogs that were homozygotes
(22%) 7 Gs, revealing the presence of a high insertion mutation
frequency (c.279insG) in theMPV17 gene in Boxers, including the
reference Boxer (Fig. 1). The later release of the reference MPV17
nucleotide sequence (XM_848683.2) has been corrected (6 Gs).
Collectively, these results also demonstrate that the affected
Chihuahua has normal MPV17 with 6 Gs and the gene is not
associated with the disease.
Canine MPV17 has 7 exons and encodes a well-conserved 176
amino acid protein (Fig. 2). The insertion mutation in exon 4 causes
a frameshift after the first 96 amino acids and results in a truncation
in the middle of the coding region (p.F96LfsX43) (Figs 1 and 2).
MPV17 mutation is recurrent
We next wanted to know whether the insertion mutation is recurrent
and exists in other breeds. We genotyped 873 additional dogs from
46 breeds (supplementary material Table S1). We found high carrier
frequencies in five additional breeds (Bull Terrier 18.2%, Dalmatian
16.7%, Papillon 32.6%, Phalene 41.2% and Pyrenean Sheepdog
7.7%), including homozygous dogs in three of them (Bull Terrier
2.3%, Papillon 4.7% and Phalene 2.2%).
Insertion mutation decreasesMPV17mRNA expression
We next analyzed whether the mutation has any effect on the
MPV17 mRNA expression. Total RNA was isolated from whole
blood samples from four dogs representing all genotypes (two dogs
homozygous for the mutation) and MPV17 expression levels were
quantified by qPCR. We found almost 20% decrease in the
heterozygote dog (0.84, s.d. 0.19) and almost 50% decrease in the
two homozygotes (0.55 and 0.56, s.d. 0.12 and 0.11) as compared
with the wild type dog (1, s.d. 0.1) (Fig. 3).
The truncatedMPV17protein is not expressed in transfected
cells
The insertion mutation leads to a frameshift in the middle of the
MPV17 protein with 43 altered amino acids before truncation
(Fig. 2). Our RNA study demonstrated significant decrease but not
complete degradation of the mutated MPV17 transcript, allowing
potential translation of the truncated protein. We investigated the
potential pathological effect of the mutation on protein expression in
transfected cells. Wild type and mutatedMPV17 cDNAs with an in-
frame HA tag at the C-terminus of the protein were transduced by
retrovirus into MEFs. Immunoblotting of whole cell lysates
indicates a complete lack of the truncated MPV17 protein,
suggesting it is highly unstable (Fig. 4).
Unfortunately we did not have access to mitochondria-rich
tissues from the affected dogs for proper replication of the cell
culture finding of MPV17 instability. However, given the early
frame-shift mutation, it is very unlikely that any expression would
be found in the affected dogs either.
HomozygousMPV17mutation is not associated with
specific conditions
MPV17 defects have been associated with severe recessive
hepatocerebral complications in human and renal and auditory
defects in mice. Similar conditions would be expected in the
genetically affected dogs lacking MPV17. We compiled all owner-
reported health information but did not find any enrichment of any
particular diseases in the genetically affected dogs in any breeds
(supplementary material Table S2). The wild type, heterozygous
and homozygous dogs were reported to have many conditions,
including different cancers, various kidney diseases, different heart
disorders and vertebral column alterations such as spondylosis.
DISCUSSION
We describe here an insertion mutation in the canine MPV17 gene.
The mutation occurs in a repeat region at exon 4. While the normal
coding sequence includes six consecutive guanines, mutation adds
the seventh guanine resulting in the frameshift and early truncation
of the MPV17 protein. Mutation destabilizes the mutated MPV17
Fig. 1. The canine MPV17 insertion
mutation. (A) Partial nucleotide and amino
acid sequences of Boxers that are wild type
or homozygous for the insertion mutation.
The insertion of an extra G is marked by
arrow and bolded. The altered amino acid
sequence is underlined. Premature STOP
codon is highlighted with grey and marked
with asterisk. The border of exons 3 and 4
are marked by a line. (B) Exonic structure of
MPV17 (not in scale). The position of the
insertion mutation is marked by an arrow.
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transcript in the lymphocytes and prevents its translation in the
transfected cells. Mutation is recurrent and present in several
unrelated breeds with a high enrichment in Boxers with aMendelian
distribution of different genotypes. Recurrence may refer to the
instability of the genomic region.
MPV17 defects have been associated with various recessive
clinical phenotypes across species including human, mouse and
zebrafish. Human MPV17 mutations cause hepatocerebral forms of
MDS with variable onset and expression (Karadimas et al., 2006;
Spinazzola et al., 2006, 2008; El-Hattab et al., 2010). More than 30
different mutations have been found in human patients, many
associated with mosaic mtDNA depletion in fibroblasts. Tissue-
specific mosaicism has been suggested to explain observed
variability of the clinical manifestations (Uusimaa et al., 2013). In
Mpv17-deficient mice, the phenotype is milder and symptoms
occur mostly at later age affecting mainly the kidneys, skin and the
hearing system (Viscomi et al., 2009; Meyer zum Gottesberge et al.,
2012). In the zebrafish, defective mpv17 altered only skin
Fig. 2. Comparison of MPV17 protein
sequences in five mammalian species.
The truncation alters the C-terminus in
MPV17. The site of the first substitution and
initiation of the frameshift is marked with an
arrow and with grey background.
Fig. 3. The MPV17 mRNA expression in canine
lymphocytes. Expression of the MPV17 mRNA decreases in
heterozygous and homozygous dog (mutant a and b)
compared to wild type dog. Expression levels in heterozygous
and homozygous dogs were normalized using the wild type
dog. Error bars indicate the standard deviations from six
replicates.
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pigmentation and normal viability of the mpv17-deficient fishes
was suggested to result from the functional redundance of the
mpv17 paralogues (Krauss et al., 2013).
Despite severe MPV17 truncation, the homozygous dogs did
not manifest any observable phenotypes previously described in
other species but were reported to be living normal lives
comparable to the heterozygous and wild type dogs. The lack of
a consistent phenotype in dogs is surprising but there could be
several reasons.
First, the genetically affected dogs could manifest a late-onset
phenotype, which was not yet observable in our study populations.
Regardless of the MPV17 genotype, many of our study dogs,
especially Boxers, had died around 8 years of age, which is an
average age of the lifespan in the breed according to the statistics of
the Finnish dog registry. The most symptoms in Mpv17-deficient
mice were reported only at the last quarter of the life (Viscomi et al.,
2009; Meyer zum Gottesberge et al., 2012). Late-onset
manifestation is recently reported also in human patients (Blakely
et al., 2012; Garone et al., 2012). It is possible that genetically
affected dogs (Boxers) do not live long enough to manifest typical
human MDS-like symptoms or symptoms observed in other
species. We could not associate the MPV17 truncation with any
consistent pigmentation changes in our dogs as previously reported
in mice and zebrafish.
Second, canine MPV17 defect may cause either very mild
symptoms or symptoms that manifest only in a particular tissue
and physiological state or in relation to a specific diet (Bottani
et al., 2013). The owners cannot distinct subtle clinical issues
without careful veterinary consultation including a comprehensive
clinical workup. Clinical heterogeneity could be further
complicated by the presence of mosaic tissue-specific mtDNA
depletion observed in human patients (Uusimaa et al., 2013).
MPV17 defects lead to mtDNA depletion in human (Wong et al.,
2007; Al-Hussaini et al., 2014) and in mouse (Viscomi et al.,
2009). We measured mtDNA depletion in canine blood samples
but results were ambiguous and inconclusive, suggesting that the
experiment should be repeated in proper tissue samples such as
liver or muscle when available.
Third, other functional mechanisms may compensate MPV17
functions in dogs. The enhancement of mtDNA transcription was
measured in the Mpv17-deficent mouse liver and muscle (Viscomi
et al., 2009). We did not have relevant tissue material available this
time from dogs to investigate this possibility. In zebrafish, genomic
redundancy with mpv17-like paralogues was proposed as a
complementary mechanism. Despite careful bioinformatics
analyses, we did not find MPV17 redundancy in the canine
genome. We found only two genomic regions on chromosomes 36
and X with incomplete and short nucleotide sequence similarity
(approximately 1700 bp and 600 bp, respectively).
Finally, our study revealed the insertion mutation in several
unrelated breeds with different genetic backgrounds. It is possible
that a modifier gene could protect the homozygous dogs from
clinical symptoms in one or several breeds. However, the fact that
none of the genetically affected dogs in any of our affected breeds
manifested the expected MDS-like clinical symptoms suggests the
lack of breed-specific modifiers. However, further follow up and
modifier studies are warranted if larger and clinically detailed
cohorts can be established.
In summary, we have found a severe truncation in canineMPV17
without associations to specific conditions. Given the severe and
variable clinical manifestations that have been linked to MPV17
defect across species, the lack of common phenotypes in dogs is
unexpected. Further functional and follow-up studies are needed to
find out whether this is due to late onset or mild symptoms or
whether there exist compensatory mechanisms for MPV17
functions. Our dogs provide exciting models to further investigate
MPV17 function and role in mitochondrial biology and disease.
MATERIALS AND METHODS
Study cohorts
The project started from a Spanish 3-year old Chihuahua dog, which was
reported to have hereditary sensitive neuropathy including some of the
symptoms of the hepatocerebral MDS (Holve et al., 1999). The Chihuahua
was clinically diagnosed with spinal gangliopathy and secondary
degenerative myelopathy. A paraffin-embedded tissue specimen for DNA
analysis was received from Banc de Teixits Animals de Catalunya (BTAC),
Departament de Medicina i Cirurgia Animals, Facultat de Veterinària,
Universitat Autònoma de Barcelona, 08193 Bellaterra (Cerdanyola del
Valles̀), Barcelona, Spain. The rest of the dogs in the study were selected
from our canine DNA bank, including altogether 1099 dogs from 48 breeds
(supplementary material Table S1). The samples were collected under the
permission of the animal ethical committee of County Administrative Board
of Southern Finland (ESLH-2009-07827/Ym-23).
DNA isolation
The EDTA-blood samples were extracted by using a semi-automatic robot
with Chemagenic Magnetic Separation Module I (MSM I) (Chemagen
Biopolymer-Technologie AG, Baesweiler, Germany). DNA from the
Chihuahua tissue specimen was isolated using QIAamp DNA mini kit
(Qiagen, Hombrechtikon, Switzerland) according to the manufacturer’s
instructions. All DNA samples were stored at −20°C.
PCR, sequencing and fragment analysis
The coding regions and splice sites of the canine MPV17 gene
(XP_853776.2) were amplified by a standard PCR and the purified
Fig. 4. Insertion mutation prevents the translation of the mutated MPV17
protein. Wild type and mutated MPV17 cDNA were transduced into mouse
embryonic fibroblasts (MEFs) and expression of the proteins were analyzed by
western blotting from the cell lysates. The mutated MPV17 is completely
absent from the lysates. TOM40 protein was immunoblotted as a control.
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amplicons were then Sanger sequenced for variants in our core facility
(FIMM Technology Center). Sequence analyses were performed with
Sequencer v4.8 (Gene Codes Corporation, Michigan, USA). The following
primer pair GCTGATGCACTAAAGAAGATGC and ACCAAACCTGC-
CTTGTTCC was used to genotype the mutation site in different dogs. We
also developed a fragment analysis protocol for a cost-efficient screening of
larger number of dogs in various breeds with the following primer pair
GGTTTGGGTGCTCACAGAG and AGGCCATTGAGTGCTCCTACT,
including a FAM-label in the 5′-end of the forward-primer. Fragment
analysis was performed using ABI3730xl DNA Analyzer (Applied
Biosystems, California, USA) with a GeneScan™ – LIZ-500™ Size
Standard (Applied BioSystems) and data was analyzed with Peak Scanner
software v1.0 (Applied BioSystems).
RNA studies
We collected blood samples in PAXgene™ Blood RNA tubes
(PreAnalytiX, Qiagen) from four 6-year old female Boxers (one wild
type, one heterozygous and two homozygous dogs) to measure theMPV17
mRNA levels. Owners reported vertebral column alterations in the
heterozygous and the wild type dogs, and spondylosis in one of the two
homozygous dogs. Total RNAwas purified manually by using PAXgene™
Blood RNA Kit v.2 (PreAnalytiX, Qiagen) and a high capacity RNA-to-
cDNA kit (Applied Biosystems) was used for cDNA synthesis using 1 µg
RNA as a template.
We used real time quantitative PCR for quantitation of the MPV17
expression in wild type, heterozygous and mutated transcripts using beta-2-
microglobulin (B2M) as a reference (loading control). RT-PCR was
performed in 20 µl volume, containing equal amounts of cDNA from the
Boxer samples, 2× FastStart Universal SYBR Green Master (ROX) (Roche
Diagnostics GmbH, Mannheim, Germany) and 5 µM of MPV17 primers
(CACTAAAGAAGATGCTGTTGGA and GGGAGGAAACAGCCTAG-
AA) and B2M (AGACCTGTCTTTCAGCAAGG and ACACGGCAGCT-
AAACTCATC). The thermal cycling conditions included 20 s at 50°C, an
initial denaturation step 10 min at 95°C and then 40 cycles of 15 s at 95°C
and 30 s at 57°C. The melting curve was recorded from 15 s at 95°C, 60 s at
60°C, 30 s at 95°C and 15 s at 60°C. qPCR was run in 7500 Fast Real-Time
PCR System (Applied BioSystems). All the reactions were performed in six
replicates. The mean values were calculated for the replicates of each
sample. Cycle threshold (Ct) values of the reference gene, B2M, were
utilized to normalize the Ct-values for each sample describing the MPV17
expression using the equation ΔCt=meanCtMPV17−meanCtB2M. The relative
MPV17 expression levels for homozygous and heterozygous dogs were
calculated using the wild type sample as a calibrator. The relative expression
for each genotype was determinated from the following equation: 2(−ΔΔCt),
where ΔΔCt=ΔCtgenotype−ΔCtcalibrator (Bookout and Mangelsdorf, 2003).
Protein analyses
The cDNA for wild type and mutantMPV17 with a C-terminal HA-epitope
tag was cloned into a Gateway (Invitrogen, California, USA) converted
retroviral expression vector pBABE-puro. Retrovirus was generated by
transient transfection into the Phoenix amphotropic packaging line and
transduced into mouse embryonic fibroblasts (MEF). Following antibiotic
selection, cells were directly used in experiments. MEFs were solubilized
in phosphate buffered saline, 1% dodecyl-maltoside, 1 mM PMSF
(phenylmethylsulfonyl fluoride). Protein concentrations were measured
by the Bradford assay (BioRAD, California, USA). Equal amounts of
proteins were separated by Tris-Glycine SDS-PAGE and transferred to
nitrocellulose by semi-dry transfer. Primary antibodies (anti-HA, Sigma-
Aldrich, Missouri, USA; anti-Tom40, Santa Cruz Biotech, Texas, USA)
were incubated overnight at +4°C and detected the following day with
secondary HRP conjugates (Jackson ImmunoResearch, Pennsylvania,
USA) using ECL with film.
Bioinformatic and statistical analyses
ORF Finder (http://www.ncbi.nlm.nih.gov/gorf/gorf.html) was used to
predict open reading frames and ClustalW2 (https://www.ebi.ac.uk/Tools/
msa/clustalw2/) to analyze sequence conservation across species (Homo
sapiens NP_002428.1, Mus musculus NP_032648.1, Macaca mulatta
XP_001089329.2 and Bos taurus NP_001039394.1). UniProt (http://www.
uniprot.org/) was used to predict the secondary structures of MPV17.
The genotype frequencies, Hardy–Weinberg equilibrium and possible
association between the insertion allele and diseases were calculated for 180
Boxers using PLINK software (Purcell et al., 2007).
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